Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verastem

5.60
-0.2800-4.76%
Volume:1.30M
Turnover:7.37M
Market Cap:307.72M
PE:-1.60
High:5.84
Open:5.78
Low:5.58
Close:5.88
Loading ...

Verastem Exercises Option Early to License Cancer Drug VS-7375 From GenFleet

MT Newswires Live
·
14 Jan

Verastem exercises early option to license VS-7375 from GenFleet Therapeutics

TIPRANKS
·
14 Jan

BRIEF-Verastem Oncology Exercises Option Early to License VS-7375

Reuters
·
14 Jan

Verastem Oncology Exercises Option Early to License VS-7375, an Oral Kras G12d (on/off) Inhibitor, From Genfleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

THOMSON REUTERS
·
14 Jan

Verastem Inc - to File U.S. Ind Application for VS-7375 in Q1 2025

THOMSON REUTERS
·
14 Jan

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Business Wire
·
14 Jan

BRIEF-Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA

Reuters
·
13 Jan

Verastem Oncology Announces Debt Refinancing With Oberland Capital and Strategic Commercialization Partnership With IQVIA to Support Potential Launch in Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

THOMSON REUTERS
·
13 Jan

Verastem Inc - Secures $150 Million Credit Facility and $7.5 Million Equity Investment

THOMSON REUTERS
·
13 Jan

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Business Wire
·
13 Jan

BRIEF-Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
08 Jan

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
08 Jan

Verastem price target raised to $16 from $13 at RBC Capital

TIPRANKS
·
07 Jan

RBC Raises Price Target on Verastem to $16 From $13, Keeps Outperform, Speculative Risk

MT Newswires Live
·
07 Jan

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Zacks
·
02 Jan

Verastem Shares Soar on FDA Priority Review of Cancer Treatment

Dow Jones
·
01 Jan

Sector Update: Health Care Stocks Lower in Afternoon Trading

MT Newswires Live
·
01 Jan

US Equity Indexes Decline After Midday Tuesday as 2024 Draws to Close

MT Newswires Live
·
01 Jan

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application

GuruFocus.com
·
31 Dec 2024

Verastem Shares up 32% After FDA Grants Priority Review for Ovarian Cancer Combo Therapy

THOMSON REUTERS
·
31 Dec 2024